TGF-beta 2 als therapeutische Zielstruktur bei cholestatischer Leberfibrose

Anne Dropmann(University Hospital Heidelberg), NM Meindl-Beinker(Heidelberg University), Ana Stojanovic(University of Mannheim), S Ghafoori(Heidelberg University), Hanna Korhonen(Heidelberg University), Adelheid Cerwenka(University of Mannheim), Steven Dooley(Heidelberg University), Katja Wosikowski(Isarna Therapeutics (Germany)), Martin A. Ebert(Heidelberg University), Michel Janicot(Isarna Therapeutics (Germany)), Albrecht Piiper(Goethe University Frankfurt), V Nalewaja(Heidelberg University), Andreas Teufel(Johannes Gutenberg University Mainz), Seddik Hammad(South Valley University), Timo Gaiser(University of Mannheim), Stefan Woelfl(Heidelberg University), Bedair Dewidar(Tanta University)
Zeitschrift für Gastroenterologie
August 13, 2019
10.1055/s-0039-1695252
Cited by 0

Related Papers

Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial
|The Lancet|2019|2.6k
Predicting survival from colorectal cancer histology slides using deep learning: A retrospective multicenter study
|PLoS Medicine|2019|1.1k
TGF-β in Hepatic Stellate Cell Activation and Liver Fibrogenesis—Updated 2019
|Cells|2019|822
Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial
|The Lancet Oncology|2016|738
<scp>TGF</scp>‐β signalling and liver disease
|FEBS Journal|2016|611